Cipla’s arm receives two inspectional observations from USFDA
InvaGen has received two inspectional observations for its manufacturing facility located in Long Island
Cipla’s wholly owned subsidiary -- InvaGen Pharmaceuticals, Inc. (InvaGen) has received two inspectional observations in Form 483 from United States Food and Drug Administration (USFDA) for its manufacturing facility located in Long Island, New York, USA.
The USFDA had conducted a Pre-Approval Inspection (PAI) at the said manufacturing facility from February 2, 2026 to February 9, 2026.
Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
